NET LOSS FORECAST: Takeda is expected to post a net loss of 33.1 billion yen, equivalent to $210.5 million, for the three months ended March, according to a poll of analysts by Visible Alpha. That ...
Recent share performance and business snapshot Takeda Pharmaceutical (TSE:4502) has recently been on investors’ radar after a period in which the stock fell around 10% over the past month and about 7% ...
Takeda announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in Primary Immunodeficiency Disease (PID) patients, ...
May 4 (Reuters) - Takeda Pharmaceutical said on Monday its experimental drug for primary immunodeficiency disease showed ...
After mulling its options for the past few months, Protagonist Therapeutics has decided to pocket $475 million from Takeda ...
The announcement comes on the heels of the company announcing nearly 250 layoffs at its Cambridge headquarters.
Takeda Pharmaceuticals, Japan's largest drugmaker, has undergone a sweeping transformation under CEO Christophe Weber, emerging as one of the world's leading pharmaceutical companies. The company's ...
Takeda Pharmaceutical said Tuesday it has committed up to a staggering $6 billion—including $4 billion upfront—to acquire from Nimbus Therapeutics a candidate for multiple autoimmune diseases that is ...
May 4 (Reuters) - Takeda Pharmaceutical said on Monday its experimental drug for primary immunodeficiency disease, a rare ...
Takeda Pharmaceutical struck one of the biggest life science deals of 2022, acquiring a clinical-stage Nimbus Therapeutics drug addressing a promising new target for autoimmune disorders. Other than ...
VELA to operate the world's first sailing cargo trimaran powered by 100 percent wind when at sea1 to sail between Europe and the U.S. Takeda to become the first biopharmaceutical company to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results